Special Issue "Molecular Correlates of the Disease Outcome"

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Systems Biology".

Deadline for manuscript submissions: closed (1 July 2020).

Special Issue Editor

Prof. Dr. Juilee Thakar
Guest Editor
University of Rochester Medical Center, School of Medicine and Dentistry, 601 Elmwood Ave, Box 672, Rochester, NY 14642, USA
Interests: quantitative biology; immunology; network modeling; infectious diseases

Special Issue Information

Translational studies use high-throughput assays (for example, metabolomics, proteomics, and transcriptomics) to investigate underlying molecular processes and to identify targets for treatment. Analysis of these data to obtain useful markers of disease is nontrivial and requires complex analytical techniques for data processing, integration, and interpretation. Thus, research focusing on multiomics data to identify disease drivers would be of interest to this Special Issue. Broadly, this topic is related to human immunology, systems biology, and personalized medicine.

Dear Colleagues,

Recent breakthroughs in high-throughput technologies such as proteomics, metabolomics, and transcriptomics enable measurements of thousands of biomolecules to investigate dysregulations during diseases. Moreover, collaborations with clinicians have facilitated sampling of multiple human tissues in order to study disease pathology in humans. Different high-throughput assays provide complimentary information to investigate underlying molecular mechanisms and thus identify novel disease drivers that can be targeted for treatment. However, obtaining relevant information from huge amounts of data, its interpretation, and integrations is nontrivial.

In human biology, defining molecular signatures underlying disease outcome is difficult due to variation in the inter- and intra-individual measurement, history, and other demographic variables, among other variables introduced by study-design. Advanced computational techniques for data interpretation, integration of multiomics data, and incorporation of existing data and knowledge are required.

Thus, the purpose of this issue is on identifying disease drivers from high-throughput multiomics approaches and to present innovative ways to quantitatively describe the molecular data that are most relevant to study disease outcome in humans.

Prof. Dr. Juilee Thakar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • translational studies
  • multiomics data
  • data integration and interpretation
  • data analytics
  • systems biology

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop